EUVIMEDOpdag EUVIMED
Multizentrische Studie

Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis

Rafael Amorim Belo Nunes, Álvaro Avezum, Mariana de Oliveira Marques, Otavio Cesar Carvalho Guimarães Baiocchi, Philip Bachour

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05921-7 ↗

At a glance

Multizentrische Studie in Annals of Hematology, 2024. Written by Rafael Amorim Belo Nunes and 4 co-authors. Institution: Department of Cardiology, Hospital Alemão Oswaldo Cruz, Rua Treze de Maio 1815, 1º subsolo Bloco B, Bela Vista, São Paulo, SP, 01323-020, Brazil. ra.…. Major MEDLINE topics: Leukemia, Lymphocytic, Chronic, B-Cell, Piperidines, Adenine, Pyrazines. Cited 12 times so far (Crossref); 25 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Bruton tyrosine kinase (BTK) inhibitors play an important role in targeted treatment of B-cell lymphoproliferative disorders. However, adverse events may limit the proper course of treatment in many patients. The purpose of this study is to compare the risk of cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL) treated with the first-generation BTK inhibitor ibrutinib versus second-generation acalabrutinib, using real-world data from a collaborative multinational network. We used data from the network (TriNetX), which encompasses more than 100 healthcare organizations worldwide. We queried the database for patients aged ≥ 18 years with chronic lymphocytic leukemia or small-cell lymphomas treated with ibrutinib or acalabrutinib in the past ten years before the analysis. We used propensity score matching to balance the cohorts. The 3-year cumulative incidences and hazard ratios for the following outcomes were calculated: atrial flutter or fibrillation, other arrhythmias, heart failure, ischemic stroke or peripheral embolism, acute coronary syndrome, bleeding, and sepsis. We compared 2,107 patients in each group. Atrial fibrillation or flutter occurred in 150 (7.1%) patients with acalabrutinib and 310 (14.7%) patients with ibrutinib during the 3-year follow-up (hazard ratio, 0.68, 95% CI 0.55-0.84). New-onset hypertension occurred in 342 (16.3%) patients in the acalabrutinib group and 584 (27.7%) patients in the ibrutinib group (hazard ratio 0.81, 95% CI 0.66-0.98). Sepsis was diagnosed in 136 (6.5%) patients in the acalabrutinib group versus 239 (11.3%) patients in the ibrutinib group (hazard ratio 0.77, 95 CI 0.60-0.98). The two groups had no significant differences concerning the other adverse events. In a large retrospective cohort using real-world data from electronic medical registers, patients with CLL or SLL treated with acalabrutinib had a better cardiovascular and non-cardiovascular safety profile than those treated with ibrutinib, with lower risks of atrial flutter or fibrillation, new-onset arterial hypertension, and sepsis.

Subjects

MeSH terms (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellPiperidinesAdeninePyrazinesAgammaglobulinaemia Tyrosine KinaseBenzamidesProtein Kinase InhibitorsHumansMaleFemaleAgedMiddle AgedPyrimidinesAged, 80 and overPyrazolesCardiovascular DiseasesRetrospective StudiesAdultTyrosine Kinase Inhibitors

Author keywords

AcalabrutinibAdverse eventsAtrial fibrillationBruton tyrosine kinase (BTK) inhibitorsCardiotoxicityChronic lymphocytic leukemiaHypertensionIbrutinibSepsisSmall cell lymphocytic lymphoma

Substances

acalabrutinibibrutinibPiperidinesAdeninePyrazinesAgammaglobulinaemia Tyrosine KinaseBenzamidesProtein Kinase InhibitorsPyrimidinesPyrazoles

Authors and institutions

  • Department of Cardiology, Hospital Alemão Oswaldo Cruz, Rua Treze de Maio 1815, 1º subsolo Bloco B, Bela Vista, São Paulo, SP, 01323-020, Brazil. ra.nunes16@gmail.com.
  • Department of Cardiology, Hospital Alemão Oswaldo Cruz, Rua Treze de Maio 1815, 1º subsolo Bloco B, Bela Vista, São Paulo, SP, 01323-020, Brazil.
  • Department of Hematology and Bone Marrow Transplant, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.

Cite

APA

Nunes, R. A. B., Avezum, Á., de Oliveira Marques, M., Baiocchi, O. C. C. G., & Bachour, P. (2024). Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis. Annals of Hematology. https://doi.org/10.1007/s00277-024-05921-7

Vancouver

Nunes RAB, Avezum Á, de Oliveira Marques M, Baiocchi OCCG, Bachour P. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis. Annals of Hematology. 2024. doi:10.1007/s00277-024-05921-7

BibTeX
@article{Nunes2024,
  author = {Nunes, Rafael Amorim Belo and Avezum, Álvaro and de Oliveira Marques, Mariana and Baiocchi, Otavio Cesar Carvalho Guimarães and Bachour, Philip},
  title = {Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05921-7}
}
Start for free →